These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15762970)

  • 1. The effect of physical training on bone mineral density in women with endometriosis treated with GnRH analogs: a pilot study.
    Bergström I; Freyschuss B; Jacobsson H; Landgren BM
    Acta Obstet Gynecol Scand; 2005 Apr; 84(4):380-3. PubMed ID: 15762970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
    Fogelman I; Blake GM; Blamey R; Palmer M; Sauerbrei W; Schumacher M; Serin D; Stewart A; Wilpshaar W
    Osteoporos Int; 2003 Dec; 14(12):1001-6. PubMed ID: 14530912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment.
    Paoletti AM; Serra GG; Cagnacci A; Vacca AM; Guerriero S; Solla E; Melis GB
    Fertil Steril; 1996 Apr; 65(4):707-10. PubMed ID: 8654625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs.
    Mittan D; Lee S; Miller E; Perez RC; Basler JW; Bruder JM
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3656-61. PubMed ID: 12161491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone mass in endometriosis patients treated with GnRH agonist implant or danazol.
    Dodin S; Lemay A; Maheux R; Dumont M; Turcot-Lemay L
    Obstet Gynecol; 1991 Mar; 77(3):410-5. PubMed ID: 1825135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis.
    Finkelstein JS; Arnold AL
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1214-9. PubMed ID: 10199756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up.
    Pierce SJ; Gazvani MR; Farquharson RG
    Fertil Steril; 2000 Nov; 74(5):964-8. PubMed ID: 11056241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical efficacy and safety of gonadotropin releasing hormone agonist combined with estrogen-dydrogesteronea in treatment of endometriosis].
    Long QQ; Zhang SF; Han Y; Chen H; Li XL; Hua KQ; Hu WG
    Zhonghua Fu Chan Ke Za Zhi; 2010 Apr; 45(4):247-51. PubMed ID: 20646533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of GnRH analogues on bone density in the vertebral column and the femur].
    Perrone G; Galoppi P; Critelli C; Bazzoffi R; Capri O; Barillaro F; Zichella L
    Minerva Ginecol; 1995 Oct; 47(10):461-5. PubMed ID: 8559437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of add-back therapy in treatment of endometriosis: a meta-analysis.
    Wu D; Hu M; Hong L; Hong S; Ding W; Min J; Fang G; Guo W
    Arch Gynecol Obstet; 2014 Sep; 290(3):513-23. PubMed ID: 24728145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High bone density in hyperandrogenic women: effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement.
    Simberg N; Tiitinen A; Silfvast A; Viinikka L; Ylikorkala O
    J Clin Endocrinol Metab; 1996 Feb; 81(2):646-51. PubMed ID: 8636283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
    Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
    J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physical training and hormone replacement therapy reduce the decrease in bone mineral density in perimenopausal women: a pilot study.
    Bergström I; Freyschuss B; Landgren BM
    Osteoporos Int; 2005 Jul; 16(7):823-8. PubMed ID: 15536539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three year followup of bone mineral density change in premenopausal women with systemic lupus erythematosus.
    Kipen Y; Briganti E; Strauss B; Will R; Littlejohn G; Morand E
    J Rheumatol; 1999 Feb; 26(2):310-7. PubMed ID: 9972964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone gained from physical activity and lost through detraining: a longitudinal study in young males.
    Nordström A; Olsson T; Nordström P
    Osteoporos Int; 2005 Jul; 16(7):835-41. PubMed ID: 15517188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin.
    Sillem M; Parviz M; Woitge HW; Kiesel L; Ulrich U; von Holst T; Runnebaum B; Ziegler R; Seibel MJ
    Exp Clin Endocrinol Diabetes; 1999; 107(6):379-85. PubMed ID: 10543415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy.
    Ripps BA; VanGilder K; Minhas B; Welford M; Mamish Z
    J Reprod Med; 2003 Oct; 48(10):761-6. PubMed ID: 14619641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of gonadotrophin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis.
    Compston JE; Yamaguchi K; Croucher PI; Garrahan NJ; Lindsay PC; Shaw RW
    Bone; 1995 Feb; 16(2):261-7. PubMed ID: 7756056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.